Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 314-322

  Chora, Inês ^a,b   Guiducci, Serena ^b   Manetti, Mirko ^b   Romano, Eloisa ^b   Mazzotta, Celestina ^b   Bellando Randone, Silvia ^b   Ibba Manneschi, Lidia ^b   Matucci Cerinic, Marco ^b   Soares, Raquel ^c  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF FLORENCE   (Italy)

^c University of Porto   (Portugal)

Author keywords

Angiogenesis; Biomarkers; Capillaroscopy; Digital ulcers; Systemic sclerosis (scleroderma); Vasculopathy

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; BIOLOGICAL MARKER; CD36 ANTIGEN; CELL ADHESION MOLECULE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; ENDOGLIN; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GALECTIN 3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; RANTES; TIE 1 RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; ANGIOSTATIC PROTEIN; CHEMOKINE;

ANGIOGENESIS; BLOOD VESSEL INJURY; CAPILLAROSCOPY; CAPILLARY DENSITY; CELL INTERACTION; CORRELATIONAL STUDY; DISEASE COURSE; ENDOTHELIUM CELL; FINGER ULCER; HUMAN; NAILFOLD VIDEOCAPILLAROSCOPY; PERIPHERAL VASCULAR DISEASE; REVIEW; SYSTEMIC SCLEROSIS; ANGIOSCOPY; AUTOIMMUNITY; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SKIN ULCER;

ANGIOSTATIC PROTEINS; AUTOIMMUNITY; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHEMOKINES; HUMANS; MICROSCOPIC ANGIOSCOPY; PERIPHERAL VASCULAR DISEASES; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 84923114126     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.001     Document Type: Review

References (89)

1. Castro S.V., Jimenez S.A. Biomarkers in systemic sclerosis. Biomark Med 2010, 4(1):133-147.
2. Manetti M., Guiducci S., Romano E., Rosa I., Ceccarelli C., Mello T., et al. Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. Arthritis Rheum 2013, 65(1):247-257.
3. Manetti M., Guiducci S., Romano E., Bellando-Randone M.L., Conforti L., Ibba-Manneschi L., et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012, 71(6):1064-1072.
4. Gilbane A.J., Denton C.P., Holmes A.M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013, 15(3):215.
5. Bassyouni I.H., Gheita T.A., Talaat R.M. Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data. Rheumatology (Oxford) 2011, 50(11):2108-2112.
6. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Review: Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013, 65(8):1953-1962.
7. Koenig M., Joyal F., Fritzler M.J., Roussin A., Abrahamowicz M., Boire G., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58(12):3902-3912.
8. Matucci-Cerinic M., Steen V., Nash P., Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford) 2009, 48(Suppl. 3):8-13.
9. Manetti M., Guiducci S., Ibba-Manneschi L., Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010, 14(6A):1241-1254.
10. Prete M., Fatone M.C., Favoino E., Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev 2014, 13(6):655-667.
11. Jinnin M., Makino T., Kajihara I., Honda N., Makino K., Ogata A., et al. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br J Dermatol 2010, 162(4):751-758.
12. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12(11):1058-1063.
13. Hummers L.K. Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford) 2008, 47(Suppl. 5):v21-v22.
14. Liakouli V., Cipriani P., Marrelli A., Alvaro S., Ruscitti P., Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011, 10(10):590-594.
15. Lambova S.N., Muller-Ladner U. Capillaroscopic pattern in systemic sclerosis-an association with dynamics of processes of angio- and vasculogenesis. Microvasc Res 2010, 80(3):534-539.
16. Riccieri V., Stefanantoni K., Vasile M., Macrì V., Sciarra I., Iannace N., et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin. Exp. Rheumatol. 2011, 29:S46-S52.
17. Rabquer B.J., Koch A.E. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012, 14(1):56-63.
18. Distler O., Del Rosso A., Giacomelli R., Cipriani P., Conforti M.L., Guiducci S., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4(6):R11.
19. Maricq H.R., LeRoy E.C., D'Angelo W.A., Medsger T.A., Rodnan G.P., Sharp G.C., et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980, 23(2):183-189.
20. Cutolo M., Sulli A., Pizzorni C., Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000, 27:155-160.
21. Ingegnoli F., Gualtierotti R. A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis. Expert Rev Clin Immunol 2013, 9(11):1091-1097.
22. Rossi D., Russo A., Manna E., Binello G., Baldovino S., Sciascia S., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12(8):821-825.
23. Cutolo M., Sulli A., Smith V. Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover?. Expert Rev Clin Immunol 2011, 7(4):395-397.
24. Kayser C., Sekiyama J.Y., Próspero L.C., Camargo C.Z., Andrade L.E. Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. Clinical Exp Rheumatol 2013, 31(2 Suppl 76):103-108.
25. Marino Claverie L., Knobel E., Takashima L., Techera L., Oliver M., Gonzalez P., et al. Organ involvement in Argentinian systemic sclerosis patients with "late" pattern as compared to patients with "early/active" pattern by nailfold capillaroscopy. Clin Rheumatol 2013, 32(6):839-843.
26. Bruni C., Guiducci S., Bellando-Randone S., Lepri G., Braschi F., Fiori G., et al. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 2014, [pii:keu296, Epub ahead of print].
27. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007, 34(12):2423-2430.
28. Steen V., Denton C.P., Pope J.E., Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl. 3):19-24.
29. Walker U.A., Tyndall A., Czirják L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66(6):754-763.
30. Amanzi L., Braschi F., Fiori G., Galluccio F., Miniati I., Guiducci S., et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010, 49(7):1374-1382.
31. Guillevin L., Hunsche E., Denton C.P., Krieg T., Schwierin B., Rosenberg D., et al. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clin Exp Rheumatol 2013, 31(2 Suppl 76):71-80.
32. Avouac J., Meune C., Ruiz B., Couraud P.O., Uzan G., Boileau C., et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 2012, 71(3):394-399.
33. Koch A.E., Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007, 9(Suppl. 2):S3.
34. Kuryliszyn-Moskal A., Klimiuk P.A., Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005, 24(2):111-116.
35. Sfikakis P.P., Tesar J., Baraf H., Lipnick R., Klipple G., Tsokos G.C. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993, 68(1):88-92.
36. Avouac J., Vallucci M., Smith V., Senet P., Ruiz B., Sulli A., et al. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 2013, 15(2):R55.
37. Valim V., Assis L.S., Simões M.F., Trevisani V.F., Pucinelli M.L., Andrade L.E. Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis. Braz J Med Biol Res 2004, 37(9):1423-1427.
38. Valentini G., Marcoccia A., Cuomo G., Vettori S., Iudici M., Bondanini F., et al. Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 2013, 15(3):R63.
39. Hasegawa M., Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci 2008, 13:3637-3647.
40. Bandinelli F., Del Rosso A., Gabrielli A., Giacomelli R., Bartoli F., Guiducci S., et al. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 2012, 30(Suppl. 71):S44-S49.
41. Distler J.H., Akhmetshina A., Schett G., Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009, 48(2):98-103.
42. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.K., Impens A.J., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13(1):R18.
43. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 2008, 47(1):45-49.
44. Ichimura Y., Asano Y., Akamata K., Takahashi T., Noda S., Taniguchi T., et al. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014, 306(4):331-338.
45. Vettori S., Cuomo G., Iudici M., D'Abrosca V., Giacco V., Barra G., et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 2014, 34(6):663-668.
46. Yanaba K., Yoshizaki A., Muroi E., Hara T., Ogawa F., Shimizu K., et al. CCL13 is a promising diagnostic marker for systemic sclerosis. Br J Dermatol 2010, 162(2):332-336.
47. Gambichler T., Yilmaz E., Höxtermann S., Yanaba K., Kolios A., Moritz R., Bechara F.G., et al. Serum CCL13 levels in patients with systemic sclerosis and controls. Br J Dermatol 2011, 165(1):216-218.
48. Yanaba K., Yoshizaki A., Muroi E., Ogawa F., Asano Y., Kadono T., et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res 2011, 303(1):29-34.
49. Choi J.J., Min D.J., Cho M.L., Min S.Y., Kim S.J., Lee S.S., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003, 30(7):1529-1533.
50. Farouk H.M., Hamza S.H., El Bakry S.A., Youssef S.S., Aly I.M., Moustafa A.A., et al. Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis 2013, 16(4):448-454.
51. Bielecki M., Kowal K., Lapinska A., Chwiesko-Minarowska S., Chyczewski L., Kowal-Bielecka O. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease. Adv Med Sci 2011, 56:255-263.
52. Solanilla A., Villeneuve J., Auguste P., Hugues M., Alioum A., Lepreux S., et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009, 48(9):1036-1044.
53. Liu Z., Lebrin F., Maring J.A., van den Driesche S., van der Brink S., van Dinther M., et al. ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis. PLoS ONE 2014, 9(1):e86273.
54. Wipff J., Avouac J., Borderie D., Zerkak D., Lemarechal H., Kahan A., et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008, 47(7):972-975.
55. Cozzani E., Javor S., Laborai E., Drosera M., Parodi A. Endothelin-1 levels in scleroderma patients: a pilot study. ISRN Dermatol 2013, 2013:125632.
56. Sulli A., Soldano S., Pizzorni C., Montagna P., Secchi M.E., Villaggio B., et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009, 36:1235-1239.
57. Kim H.S., Park M.K., Kim H.Y., Park S.H., et al. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010, 29(3):247-254.
58. Dunne J.V., Keen K.J., Van Eeden S.F. Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int 2013, 33(2):475-484.
59. Noda S., Asano Y., Aozasa N., Akamata K., Taniguchi T., Takahashi T., et al. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis. Arch Dermatol Res 2013, 305(4):325-331.
60. Michalska-Jakubus M., Kowal-Bielecka O., Chodorowska G., Bielecki M., Krasowska D. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 2011, 50(4):746-755.
61. Ichimura Y., Asano Y., Akamata K., Aozasa N., Noda S., Taniguchi T., et al. Serum angiopoietin-like protein 3 levels: possible correlation with progressive skin sclerosis, digital ulcers and pulmonary vascular involvement in patients with systemic sclerosis. Acta Derm Venereol 2014, 94(2):157-162.
62. Toyama T., Asano Y., Takahashi T., Aozasa N., Akamata K., Noda S., et al. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013, 27(3):337-344.
63. Del Rosso A., Distler O., Milia A.F., Emanueli C., Ibba-Manneschi L., Guiducci S., et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 2005, 64(3):382-387.
64. Riccieri V., Rinaldi T., Spadaro A., Scrivo R., Ceccarelli F., Franco M.D., et al. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 2003, 22(2):102-106.
65. Terras S., Opitz E., Moritz R.K., Höxtermann S., Gambichler T., Kreuter A. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis 2013, 72(1):144-145.
66. Manetti M., Guiducci S., Ceccarelli C., Romano E., Bellando-Randone S., Conforti M.L., et al. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 2011, 70:1876-1878.
67. Taniguchi T., Asano Y., Akamata K., Noda S., Masui Y., Yamada D., et al. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 2012, 39(3):539-544.
68. Yanaba K., Asano Y., Akamata K., Noda S., Aozasa N., Taniguchi T., et al. Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy. Int J Rheum Dis 2014, 10.1111/1756-185X.12288.
69. Aozasa N., Asano Y., Akamata K., Noda S., Masui Y., Yamada D., et al. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2013, 27(1):37-42.
70. Kowal-Bielecka O., Bielecki M., Guiducci S., Trzcinska-Butkiewicz B., Michalska-Jakubus M., Matucci-Cerinic M., et al. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther 2013, 15(3):R69.
71. Bielecki M., Kowal K., Lapinska A., Chwiecko J., Skowronski J., Sierakowski S., et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol 2009, 47(3):465-469.
72. Yamada D., Asano Y., Takahashi T., Masui Y., Aozasa N., Akamata K., et al. Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis. Eur J Dermatol 2012, 22(3):351-357.
73. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis & Rheumatism 2000, 43(4):889-893.
74. Manetti M., Guiducci S., Romano E., Ceccarelli C., Bellando-Randone S., Conforti M.L., et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011, 109(3):e14-e26.
75. Manetti M., Guiducci S., Ibba-Manneschi L., Matucci-Cerinic M. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 2011, 21(7):204-210.
76. Manetti M., Guiducci S., Romano E., Bellando-Randone S., Lepri G., Bruni C., et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis 2013, 72(8):1425-1427.
77. D'Alessio S., Fibbi G., Cinelli M., Guiducci S., Del Rosso A., Margheri F., et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004, 50(10):3275-3285.
78. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12(3):340-354.
79. Villalta D., Imbastaro T., Di Giovanni S., Lauriti C., Gabini M., Turi M.C., et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12(2):114-120.
80. Cipriani P., Marrelli A., Liakouli V., Di Benedetto P., Giacomelli R. Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmun Rev 2011, 10(10):641-646.
81. Zielonka T.M., Demkow U., Zycinska K., Filewska M., Korzeniewska M., Radzikowska E., et al. Angiogenic activity of sera from patients with systemic autoimmune diseases in relation to clinical, radiological and functional pulmonary status. J Physiol Pharmacol 2008, 59(Suppl. 6):791-800.
82. Riccieri V., Germano V., Alessandri C., Vasile M., Ceccarelli F., Sciarra I., et al. More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies. Are they useful tools for prognostic use in systemic sclerosis?. Clin Exp Rheumatol 2008, 26:992-997.
83. Riemekasten G., Philippe A., Näther M., Slowinski T., Müller D.N., Heidecke H., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011, 70(3):530-536.
84. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10(9):553-558.
85. Esposito G., Tamby M.C., Chanseaud Y., Servettaz A., Guillevin L., Mouthon L. Anti-annexin V antibodies: are they prothrombotic?. Autoimmun Rev 2005, 4(1):55-60.
86. Sugiura K., Muro Y. Anti-annexin V antibodies and digital ischemia in patients with scleroderma. J Rheumatol 1999, 26(10):2168-2172.
87. El Serougy I.M., Shahin A.A., Soliman D.A., Akhnoukh A.F., Mousa S.M. Clinical significance of serum anti-annexin V antibodies in Egyptian patients with scleroderma. Egypt J Immunol 2009, 16(1):1-8.
88. Habeeb R.A., Mansour H.E., Abdeldayem A.M., Abo-Shady R.A., Hassan I.A., Saafan N.K., et al. Anti-annexin v antibodies: association with vascular involvement and disease outcome in patients with systemic sclerosis. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:15-23.
89. Klein-Weigel P., Opitz C., Riemekasten G. Systemic sclerosis-a systematic overview: part 1-disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011, 40(1):6-19.